Bloodstream infections in neutropenic cancer patients: A practical update

References

• Bos MM, Smeets LS, Dumay I, de Jonge E. Bloodstream infections in patients with or without cancer in a large community hospital. Infection 2013; 41:949-58; PMID:23645474; http://dx.doi.org/10.1007/s15010-013-0468-1
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-32; PMID:8469254; http://dx.doi.org/10.1056/NEJM199305063281808
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637; PMID:23353941; http://dx.doi.org/10.1097/CCM.0b013e31827e83af
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-48; PMID:19696123; http://dx.doi.org/10.1378/chest.09-0087
   PubMed Web of Science ®Google Scholar
• Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10:1412-45; PMID:23138169
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-8; PMID:12664219; http://dx.doi.org/10.1007/s00134-003-1662-x
   PubMedGoogle Scholar
• CDC. Device associated module BSI. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection). http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf, 2016
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427-31; PMID:21205990; http://dx.doi.org/10.1093/cid/ciq147
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12; PMID:19035777; http://dx.doi.org/10.1086/595011
   PubMed Web of Science ®Google Scholar
• Kostyanev T, Bonten MJ, O'Brien S, Steel H, Ross S, Francois B, Tacconelli E, Winterhalter M, Stavenger RA, Karlen A, et al. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother 2016; 71:290-5; PMID:26568581; http://dx.doi.org/10.1093/jac/dkv339
   PubMed Web of Science ®Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Annual epidemiological report 2014 of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance and healthcare-associated infections. Stockholm: ECDC; Available at: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2014.pdf. 2015
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81; PMID:21793988; http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98:1826-35; PMID:24323983; http://dx.doi.org/10.3324/haematol.2013.091025
   PubMed Web of Science ®Google Scholar
• Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009; 15:224-31; PMID:19335370; http://dx.doi.org/10.1111/j.1469-0691.2009.02739.x
   PubMed Web of Science ®Google Scholar
• Castagnola E, Caviglia I, Pescetto L, Bagnasco F, Haupt R, Bandettini R. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia. Future Microbiol 2015; 10:357-64; PMID:25812459; http://dx.doi.org/10.2217/fmb.14.144
   PubMed Web of Science ®Google Scholar
• Bow EJ. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 2013; 68:492-5; PMID:23299574; http://dx.doi.org/10.1093/jac/dks512
   PubMed Web of Science ®Google Scholar
• Heidenreich D, Kreil S, Nolte F, Reinwald M, Hofmann WK, Klein SA. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis. Ann Hematol 2016; 95:287-93; PMID:26494235.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Lingaratnam S, Mileshkin L, Booth DL, Cain MJ, Ritchie DS, Wei A, Thursky KA. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:102-9; PMID:21272174; http://dx.doi.org/10.1111/j.1445-5994.2010.02341.x
   PubMed Web of Science ®Google Scholar
• Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, Salvado M, Grau S, Horcajada JP, Montero MM, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res 2012; 12:122; PMID:22621745; http://dx.doi.org/10.1186/1472-6963-12-122
   PubMed Web of Science ®Google Scholar
• Vasudevan A, Memon BI, Mukhopadhyay A, Li J, Tambyah PA. The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study. Antimicrob Resist Infect Control 2015; 4:3; PMID:25653851; http://dx.doi.org/10.1186/s13756-015-0045-8
   PubMed Web of Science ®Google Scholar
• Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, Norasetthada L, Chan T, Kwong YL, Vaid AK, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect 2015; 21:594.e7-.e11; PMID:25749561
   PubMedGoogle Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100; PMID:20218877; http://dx.doi.org/10.1086/651263
   PubMed Web of Science ®Google Scholar
• Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39 Suppl 1:S32-7; PMID:15250018; http://dx.doi.org/10.1086/383050
   PubMedGoogle Scholar
• Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. J Oncol Pract 2015; 11:47-54; PMID:25491042
   PubMed Web of Science ®Google Scholar
• Liu CY, Lai YC, Huang LJ, Yang YW, Chen TL, Hsiao LT, Liu JH, Gau JP, Chen PM, Tzeng CH, et al. Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 2011; 46:1231-9; PMID:21113186; http://dx.doi.org/10.1038/bmt.2010.286
   PubMed Web of Science ®Google Scholar
• Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol 2014; 93:1083-95; PMID:24777705; http://dx.doi.org/10.1007/s00277-014-2086-0
   PubMed Web of Science ®Google Scholar
• Jeddi R, Achour M, Amor RB, Aissaoui L, Bouteraa W, Kacem K, Lakhal RB, Abid HB, BelHadjAli Z, Turki A, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 2010; 15:28-32; PMID:20132659; http://dx.doi.org/10.1179/102453310X12583347009577
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, Ki HK, Son JS, Lee SS, Kim YS, et al. Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia. J Infect 2011; 62:26-33; PMID:21056057; http://dx.doi.org/10.1016/j.jinf.2010.10.010
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36:1103-10; PMID:12715303; http://dx.doi.org/10.1086/374339
   PubMed Web of Science ®Google Scholar
• Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490-4; PMID:10530434; http://dx.doi.org/10.1086/598620
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15:291-6; PMID:8781879; http://dx.doi.org/10.1007/BF01695660
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D'Adda M, Morello E, Re A, Borlenghi E, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012; 91:1299-304; PMID:22349723; http://dx.doi.org/10.1007/s00277-012-1424-3
   PubMed Web of Science ®Google Scholar
• Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011; 15:e277-81; PMID:21324723; http://dx.doi.org/10.1016/j.ijid.2010.12.010
   PubMed Web of Science ®Google Scholar
• Gedik H, Simsek F, Kanturk A, Yildirmak T, Arica D, Aydin D, Demirel N, Yokus O. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag 2014; 10:743-52; PMID:25258539; http://dx.doi.org/10.2147/TCRM.S68450
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, Andrianaki AM, Falagas ME. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 2013; 21:2521-6; PMID:23625018; http://dx.doi.org/10.1007/s00520-013-1816-5
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, di Grazia C, Frassoni F, Bacigalupo A, Viscoli C. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009; 15:47-53; PMID:19135942; http://dx.doi.org/10.1016/j.bbmt.2008.10.024
   PubMed Web of Science ®Google Scholar
• Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, Domingo-Domenech E, Jimenez L, Carratala J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013; 19:474-9; PMID:22524597; http://dx.doi.org/10.1111/j.1469-0691.2012.03879.x
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2010; 138:1044-51; PMID:19941686; http://dx.doi.org/10.1017/S0950268809991208
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M. Fourth European Conference on Infections in Leukemia Group ajvoEEIELN, Esgich/Escmid. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014; 68:321-31; PMID:24370562; http://dx.doi.org/10.1016/j.jinf.2013.12.006
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 2014; 27:200-10; PMID:24573013; http://dx.doi.org/10.1097/QCO.0000000000000038
   PubMed Web of Science ®Google Scholar
• Sood P, Seth T, Kapil A, Sharma V, Dayama A, Sharma S, Kumar S, Singh AK, Mishra P, Mahapatra M. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc 2012; 110:439-44; PMID:23520666
   PubMedGoogle Scholar
• Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007; 45:228-33; PMID:17578784; http://dx.doi.org/10.1086/518873
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Caira M, Spadea A, Busca A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 2015; 21:337-43; PMID:25595706; http://dx.doi.org/10.1016/j.cmi.2014.11.022
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2013; 54:799-806; PMID:22916826; http://dx.doi.org/10.3109/10428194.2012.723210
   PubMed Web of Science ®Google Scholar
• Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015; 20:1-18; PMID:26675038; http://dx.doi.org/10.2807/1560-7917.ES.2015.20.45.30062.
   PubMedGoogle Scholar
• Kjellander C, Bjorkholm M, Cherif H, Kalin M, Giske CG. Hematological: Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 2012; 88:422-30; PMID:22335785; http://dx.doi.org/10.1111/j.1600-0609.2012.01768.x
   PubMed Web of Science ®Google Scholar
• Gudiol C, Ayats J, Camoez M, Dominguez MA, Garcia-Vidal C, Bodro M, Ardanuy C, Obed M, Arnan M, Antonio M, et al. Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One 2013; 8:e74734; PMID:24069339; http://dx.doi.org/10.1371/journal.pone.0074734
   PubMed Web of Science ®Google Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratala J, Gudiol F. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65:333-41; PMID:19959544; http://dx.doi.org/10.1093/jac/dkp411
   PubMed Web of Science ®Google Scholar
• Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 2013; 92:533-41; PMID:23161391; http://dx.doi.org/10.1007/s00277-012-1631-y
   PubMed Web of Science ®Google Scholar
• Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, Nair R, Kelkar R. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 2010; 47:184-8; PMID:20448384; http://dx.doi.org/10.4103/0019-509X.63019
   PubMed Web of Science ®Google Scholar
• Ke ZY, Xu L, Zhang TT, Mo YL, Huang LB, Zhang XL, Luo XQ. A prospective study of febrile episodes in inpatient children on chemotherapy. Pediatr Infect Dis J 2010; 29:968-70; PMID:20526229; http://dx.doi.org/10.1097/INF.0b013e3181e32ab2
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58:299-307; PMID:19272650; http://dx.doi.org/10.1016/j.jinf.2009.02.002
   PubMed Web of Science ®Google Scholar
• Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18:413-31; PMID:22507109; http://dx.doi.org/10.1111/j.1469-0691.2012.03821.x
   PubMed Web of Science ®Google Scholar
• Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50:282-8; PMID:25310302; http://dx.doi.org/10.1038/bmt.2014.231
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, Losito AR, Corcione S, Saffioti C, Bartoletti M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014; 20:1357-62; PMID:24980276; http://dx.doi.org/10.1111/1469-0691.12747
   PubMed Web of Science ®Google Scholar
• Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 2014; 42:5-13; PMID:23975584; http://dx.doi.org/10.1007/s15010-013-0525-9
   PubMed Web of Science ®Google Scholar
• Kim SB, Min YH, Cheong JW, Kim JS, Kim SJ, Ku NS, Jeong SJ, Han SH, Choi JY, Song YG, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis 2014; 46:81-8; PMID:24325335; http://dx.doi.org/10.3109/00365548.2013.857042
   PubMed Web of Science ®Google Scholar
• Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39:283-94; PMID:22386741; http://dx.doi.org/10.1016/j.ijantimicag.2011.12.012
   PubMed Web of Science ®Google Scholar
• Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2014; 1:Cd003914; PMID:24425445
   PubMedGoogle Scholar
• Amit S, Mishali H, Kotlovsky T, Schwaber MJ, Carmeli Y. Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors. Clin Microbiol Infect 2015; 21:30-4; PMID:25636924; http://dx.doi.org/10.1016/j.cmi.2014.08.001
   PubMed Web of Science ®Google Scholar
• Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, Mensa J. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63:568-74; PMID:19126669; http://dx.doi.org/10.1093/jac/dkn514
   PubMed Web of Science ®Google Scholar
• Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11:1053-63; PMID:24073806; http://dx.doi.org/10.1586/14787210.2013.836057
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, Bacigalupo A, Viscoli C. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 2012; 40:271-8; PMID:22187340; http://dx.doi.org/10.1007/s15010-011-0229-y
   PubMed Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30 Suppl 1:S51-9; PMID:17689933; http://dx.doi.org/10.1016/j.ijantimicag.2007.06.012
   PubMed Web of Science ®Google Scholar
• Rosa RG, Dos Santos RP, Goldani LZ. Mortality related to coagulase-negative staphylococcal bacteremia in febrile neutropenia: A cohort study. Can J Infect Dis Med Microbiol 2014; 25:e14-7; PMID:24634691
   PubMed Web of Science ®Google Scholar
• Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant 2007; 39:623-9; PMID:17384657; http://dx.doi.org/10.1038/sj.bmt.1705654
   PubMed Web of Science ®Google Scholar
• Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, Abla O, Sung L. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol 2004; 22:1222-7; PMID:15051769; http://dx.doi.org/10.1200/JCO.2004.09.108
   PubMed Web of Science ®Google Scholar
• Han SB, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK. Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children. BMC Infect Dis 2013; 13:273; PMID:23773209; http://dx.doi.org/10.1186/1471-2334-13-273
   PubMed Web of Science ®Google Scholar
• Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31:1126-30; PMID:11073739; http://dx.doi.org/10.1086/317460
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007; 13:615-21; PMID:17448922; http://dx.doi.org/10.1016/j.bbmt.2007.01.078
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola AM, Gualandi F, Van Lint MT, Dominietto A, Lamparelli T, Cappellano P, et al. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2010; 12:505-12; PMID:20636482; http://dx.doi.org/10.1111/j.1399-3062.2010.00544.x
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008; 46:30-6; PMID:18171210; http://dx.doi.org/10.1086/523588
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM, Kwon JC, Kim SH, Choi JK, Park SH, Park YJ, Choi JH, Yoo JH. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis 2013; 13:504; PMID:24164924; http://dx.doi.org/10.1186/1471-2334-13-504
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Miranda BG, Vieira MB, Dulley FL, Fonseca GG, Guimaraes T, Levin AS, Shikanai-Yasuda MA, Costa SF. Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp. Int J Infect Dis 2015; 33:171-6; PMID:25660090; http://dx.doi.org/10.1016/j.ijid.2015.02.001
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, Hernandez JR, Pascual A. Bacteremia due to extended-spectrum β -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43:1407-14; PMID:17083012; http://dx.doi.org/10.1086/508877
   PubMed Web of Science ®Google Scholar
• Wang SS, Lee NY, Hsueh PR, Huang WH, Tsui KC, Lee HC, Wu CJ, Chang CM, Huang CC, Huang CF, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect 2011; 44:282-8; PMID:21524962; http://dx.doi.org/10.1016/j.jmii.2010.08.004
   PubMedGoogle Scholar
• Moghnieh R, Estaitieh N, Mugharbil A, Jisr T, Abdallah DI, Ziade F, Sinno L, Ibrahim A. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front Cell Infect Microbiol 2015; 5:11; PMID:25729741; http://dx.doi.org/10.3389/fcimb.2015.00011
   PubMed Web of Science ®Google Scholar
• Meyer E, Beyersmann J, Bertz H, Wenzler-Rottele S, Babikir R, Schumacher M, Daschner FD, Ruden H, Dettenkofer M, Group O-KS. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant 2007; 39:173-8; PMID:17245425; http://dx.doi.org/10.1038/sj.bmt.1705561
   PubMed Web of Science ®Google Scholar
• Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995-2025; PMID:15108222; http://dx.doi.org/10.1002/cncr.20162
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98:1531-9; PMID:14508842; http://dx.doi.org/10.1002/cncr.11671
   PubMed Web of Science ®Google Scholar
• Seo SK, Xiao K, Huang YT, Jongwutiwes U, Chung D, Maloy M, Giralt S, Barker JN, Jakubowski AA, Papanicolaou GA. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study. J Infect 2014; 69:341-51; PMID:24931578; http://dx.doi.org/10.1016/j.jinf.2014.06.004
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34:1524-9; PMID:12015700; http://dx.doi.org/10.1086/340402
   PubMed Web of Science ®Google Scholar
• Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis 2014; 16:279-85; PMID:24621081; http://dx.doi.org/10.1111/tid.12195
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45; PMID:19489710; http://dx.doi.org/10.1086/599376
   PubMed Web of Science ®Google Scholar
• Mollee P, Jones M, Stackelroth J, van Kuilenburg R, Joubert W, Faoagali J, Looke D, Harper J, Clements A. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J Hosp Infect 2011; 78:26-30; PMID:21459476; http://dx.doi.org/10.1016/j.jhin.2011.01.018
   PubMed Web of Science ®Google Scholar
• Chaberny IF, Ruseva E, Sohr D, Buchholz S, Ganser A, Mattner F, Gastmeier P. Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies. Ann Hematol 2009; 88:907-12; PMID:19139891; http://dx.doi.org/10.1007/s00277-008-0687-1
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu Y, Ma X, Wei L, Chen W, Song L. The incidence and risk factors of peripherally inserted central catheter-related infection among cancer patients. Ther Clin Risk Manag 2015; 11:863-71; PMID:26045668; http://dx.doi.org/10.2147/TCRM.S83776
   PubMed Web of Science ®Google Scholar
• Cotogni P, Barbero C, Garrino C, Degiorgis C, Mussa B, De Francesco A, Pittiruti M. Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study. Support Care Cancer 2015; 23:403-9; PMID:25120012; http://dx.doi.org/10.1007/s00520-014-2387-9
   PubMed Web of Science ®Google Scholar
• Metzger KE, Rucker Y, Callaghan M, Churchill M, Jovanovic BD, Zembower TR, Bolon MK. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients. Infect Control Hosp Epidemiol 2015; 36:119-24; PMID:25632993; http://dx.doi.org/10.1017/ice.2014.38
   PubMed Web of Science ®Google Scholar
• Pagano L, Tacconelli E, Tumbarello M, Laurenti L, Ortu-La Barbera E, Antinori A, Caponera S, Cauda R, Leone G. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. Haematologica 1997; 82:415-9; PMID:9299853
   PubMed Web of Science ®Google Scholar
• Pinana JL, Montesinos P, Martino R, Vazquez L, Rovira M, Lopez J, Batlle M, Figuera A, Barba P, Lahuerta JJ, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 2014; 93:299-307; PMID:23995612; http://dx.doi.org/10.1007/s00277-013-1872-4
   PubMed Web of Science ®Google Scholar
• Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis 2014; 16:106-14; PMID:24372809; http://dx.doi.org/10.1111/tid.12175
   PubMed Web of Science ®Google Scholar
• Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients. BMC Infect Dis 2010; 10:135; PMID:20504343; http://dx.doi.org/10.1186/1471-2334-10-135
   PubMed Web of Science ®Google Scholar
• Ammann RA, Laws HJ, Schrey D, Ehlert K, Moser O, Dilloo D, Bode U, Wawer A, Schrauder A, Cario G, et al. Bloodstream infection in paediatric cancer centres–leukaemia and relapsed malignancies are independent risk factors. Eur J Pediatr 2015; 174:675-86; PMID:25804192; http://dx.doi.org/10.1007/s00431-015-2525-5
   PubMed Web of Science ®Google Scholar
• Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J, Barrios-Camacho H, Najera-Leon E, Velazquez-Acosta C, Vilar-Compte D. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer 2016; 24:253-9; PMID:26014616; http://dx.doi.org/10.1007/s00520-015-2772-z
   PubMed Web of Science ®Google Scholar
• Arnan M, Gudiol C, Calatayud L, Linares J, Dominguez MA, Batlle M, Ribera JM, Carratala J, Gudiol F. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30:355-60; PMID:21052757; http://dx.doi.org/10.1007/s10096-010-1093-x
   PubMed Web of Science ®Google Scholar
• Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794-810; PMID:23319691; http://dx.doi.org/10.1200/JCO.2012.45.8661
   PubMed Web of Science ®Google Scholar
• Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92:433-42; PMID:23412562; http://dx.doi.org/10.1007/s00277-013-1698-0
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer Suppl 2007; 5:5-12; http://dx.doi.org/10.1016/j.ejcsup.2007.06.002.
   Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-87; PMID:16148283; http://dx.doi.org/10.1056/NEJMoa044097
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988-98; PMID:16148284; http://dx.doi.org/10.1056/NEJMoa050078
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107:1743-51; PMID:16977651; http://dx.doi.org/10.1002/cncr.22205
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1:Cd004386; PMID:22258955
   PubMedGoogle Scholar
• Kimura S, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect 2014; 69:13-25; PMID:24583063; http://dx.doi.org/10.1016/j.jinf.2014.02.013
   PubMed Web of Science ®Google Scholar
• Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C, Kabbara N, Montori VM. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27:53-63; PMID:17938978; http://dx.doi.org/10.1007/s10096-007-0397-y
   PubMed Web of Science ®Google Scholar
• Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545-53; PMID:22001945; http://dx.doi.org/10.1097/QCO.0b013e32834cf054
   PubMed Web of Science ®Google Scholar
• Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 2011; 57:335-8; PMID:21912115; http://dx.doi.org/10.1159/000329661
   PubMed Web of Science ®Google Scholar
• Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24:111-8; PMID:15714332; http://dx.doi.org/10.1007/s10096-005-1278-x
   PubMed Web of Science ®Google Scholar
• Verlinden A, Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN, Gadisseur AP. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol 2014; 93:302-8; PMID:24750350; http://dx.doi.org/10.1111/ejh.12345
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010; 21 Suppl 5:v248-51; PMID:20555091; http://dx.doi.org/10.1093/annonc/mdq195
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8-32; PMID:21095116; http://dx.doi.org/10.1016/j.ejca.2010.10.013
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158-67; PMID:17634496; http://dx.doi.org/10.1200/JCO.2006.08.8823
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24:2475-84; PMID:23788754; http://dx.doi.org/10.1093/annonc/mdt226
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Kern WV, Livermore DM, Ecil ajvoEEI, ESCMID Eo. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 2013; 98:1821-5; PMID:24323982; http://dx.doi.org/10.3324/haematol.2013.091769
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1-8; PMID:26278669
   PubMed Web of Science ®Google Scholar
• Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Hantschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69:3387-92; PMID:25103492; http://dx.doi.org/10.1093/jac/dku305
   PubMed Web of Science ®Google Scholar
• Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother 2014; 58:1972-6; PMID:24419337; http://dx.doi.org/10.1128/AAC.02283-13
   PubMed Web of Science ®Google Scholar
• Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T, Gastmeier P, Eckmanns T, Rodloff AC, Kaisers UX. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents 2013; 42:565-70; PMID:24100228; http://dx.doi.org/10.1016/j.ijantimicag.2013.08.008
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, Oren I. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011; 46:1226-30; PMID:21057549; http://dx.doi.org/10.1038/bmt.2010.279
   PubMed Web of Science ®Google Scholar
• Lamoth F, Jaton K, Prod'hom G, Senn L, Bille J, Calandra T, Marchetti O. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 2010; 48:3510-6; PMID:20720024; http://dx.doi.org/10.1128/JCM.00147-10
   PubMed Web of Science ®Google Scholar
• Jordana-Lluch E, Gimenez M, Quesada MD, Rivaya B, Marco C, Dominguez MJ, Armestar F, Martro E, Ausina V. Evaluation of the Broad-Range PCR/ESI-MS Technology in Blood Specimens for the Molecular Diagnosis of Bloodstream Infections. PLoS One 2015; 10:e0140865; PMID:26474394; http://dx.doi.org/10.1371/journal.pone.0140865
   PubMed Web of Science ®Google Scholar
• Meidani M, Khorvash F, Abolghasemi H, Jamali B. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer 2013; 2:216-9; PMID:24455636; http://dx.doi.org/10.4103/2278-330X.119913
   PubMedGoogle Scholar
• Ratzinger F, Haslacher H, Perkmann T, Schmetterer KG, Poeppl W, Mitteregger D, Dorffner G, Burgmann H. Sepsis biomarkers in neutropaenic systemic inflammatory response syndrome patients on standard care wards. Eur J Clin Invest 2015; 45:815-23; PMID:26046926; http://dx.doi.org/10.1111/eci.12476
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51; PMID:10944139
   PubMed Web of Science ®Google Scholar
• Baskaran ND, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 2008; 87:563-9; PMID:18437382; http://dx.doi.org/10.1007/s00277-008-0487-7
   PubMed Web of Science ®Google Scholar
• Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004; 12:555-60; PMID:15197637
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez J, Hernando Cubero J, Espinosa J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 2015; 33:465-71; PMID:25559804; http://dx.doi.org/10.1200/JCO.2014.57.2347
   PubMed Web of Science ®Google Scholar
• Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8; PMID:10423465; http://dx.doi.org/10.1056/NEJM199907293410502
   PubMed Web of Science ®Google Scholar
• Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy–EORTC infectious diseases group trial XV. J Clin Oncol 2013; 31:1149-56; PMID:23358983; http://dx.doi.org/10.1200/JCO.2012.45.8109
   PubMed Web of Science ®Google Scholar
• Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal β-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of β-lactams. Cochrane Database Syst Rev 2010; Cd005197; PMID:21069685; http://dx.doi.org/10.1002/14651858.CD005197.pub3
   PubMed Web of Science ®Google Scholar
• Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus β-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013; 6:Cd003038; PMID:23813455
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and Treatment of Cancer-Related Infections. Version 2.2011. NCCNorg 2011
   Google Scholar
• Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40:43-9; PMID:21926615; http://dx.doi.org/10.1097/CCM.0b013e31822b50c2
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32-40; PMID:24026297; http://dx.doi.org/10.1007/s00134-013-3077-7
   PubMed Web of Science ®Google Scholar
• Heenen S, Jacobs F, Vincent JL. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med 2012; 40:1404-9; PMID:22430235; http://dx.doi.org/10.1097/CCM.0b013e3182416ecf
   PubMed Web of Science ®Google Scholar
• Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, Jaber S, Lepape A, Constantin JM, Papazian L, Bruder N, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399-408; PMID:25091790; http://dx.doi.org/10.1007/s00134-014-3411-8
   PubMed Web of Science ®Google Scholar
• Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun JP, Berger P, Duran S, Faucher M, Blache JL, et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014; 40:41-9; PMID:24231857; http://dx.doi.org/10.1007/s00134-013-3148-9
   PubMed Web of Science ®Google Scholar
• Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55:436-44; PMID:15722392; http://dx.doi.org/10.1093/jac/dki028
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:431-9; PMID:15978529; http://dx.doi.org/10.1016/S1473-3099(05)70164-X
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247-59; PMID:9332520; http://dx.doi.org/10.1086/514550
   PubMed Web of Science ®Google Scholar
• Rolston KV, Besece D, Lamp KC, Yoon M, McConnell SA, White P. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer 2014; 22:7-14; PMID:23975231; http://dx.doi.org/10.1007/s00520-013-1947-8
   PubMed Web of Science ®Google Scholar
• Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607; PMID:16447103; http://dx.doi.org/10.1086/500139
   PubMed Web of Science ®Google Scholar
• Cohen N, Mihu CN, Seo SK, Chung D, Chou J, Heller G, Papanicolaou GA. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1337-41; PMID:19747643; http://dx.doi.org/10.1016/j.bbmt.2009.05.021
   PubMed Web of Science ®Google Scholar
• Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 2013; 98:1836-47; PMID:24323984; http://dx.doi.org/10.3324/haematol.2013.091330
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50; PMID:22752516; http://dx.doi.org/10.1093/cid/cis588
   PubMed Web of Science ®Google Scholar
• Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis 2015; 2:ofv050; PMID:26125030; http://dx.doi.org/10.1093/ofid/ofv050
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13; PMID:22252816; http://dx.doi.org/10.1128/AAC.06268-11
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17:1135-41; PMID:21635663; http://dx.doi.org/10.1111/j.1469-0691.2011.03553.x
   PubMed Web of Science ®Google Scholar
• Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 2015; 46:483-93; PMID:26498989; http://dx.doi.org/10.1016/j.ijantimicag.2015.08.011
   PubMed Web of Science ®Google Scholar